|
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO). |
|
|
Employment - Tennessee Oncology/OneOncology |
|
|
|
No Relationships to Disclose |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Roche |
Research Funding - Genentech/Roche (Inst) |
Patents, Royalties, Other Intellectual Property - Listed as inventor on a pending patent application for Display screen with icon or graphical user interface |
Travel, Accommodations, Expenses - Genentech/Roche |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech/Roche; UnitedHealthcare |
Travel, Accommodations, Expenses - Genentech |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Genentech/Roche; Moderna Therapeutics |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
Patents, Royalties, Other Intellectual Property - Healthcare technology patent (I) |
|
|
Stock and Other Ownership Interests - Agilent; AstraZeneca; Bristol Myers Squibb; Novartis |
Research Funding - BeiGene; Merck; Mirati Therapeutics; Pfizer; Regeneron |
|
|
No Relationships to Disclose |
|
|
Honoraria - HMP; OncLive; OneOncology |
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Immunomedics; Seagen |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Exelixis (Inst); Merck (Inst); OBI Pharma (Inst); Roche/Genentech (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst) |
Travel, Accommodations, Expenses - Caris Life Sciences; Tempus |
|
|
No Relationships to Disclose |
|
|
Employment - Astera Cancer Care |
Leadership - Astera Cancer Care |
Research Funding - Abbvie; Arvinas; Bristol-Myers Squibb/Pfizer; Daiichi Sankyo/Astra Zeneca; Epizyme; Exelixis; Gilead/Forty Seven; ImmunityBio; Janssen Oncology; Mirati Therapeutics; natera; Novartis; Novocure; POINT Biopharma; Roche/Genentech; Veru; Zymeworks; Zymeworks |
|
|
No Relationships to Disclose |
|
|
Employment - Tennessee Oncology |
Stock and Other Ownership Interests - OneOncology |
Consulting or Advisory Role - Flatiron Health |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calistoga Pharmaceuticals (Inst); Celgene (Inst); Cephalon (Inst); Chorus (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Eisai (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncogenex (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Sarah Cannon Research Institute (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Flatiron Health; OneOncology |
Other Relationship - Sarah Cannon Research Institute (Inst) |
|
|
|
|
Speakers' Bureau - HMP; IDEOlogy Health |
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EQRx (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Guardant Health (Inst); Immunomedics (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merck (Inst); Merus NV (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst) |